Related Experiment Video
Updated: Jun 11, 2025

09:27
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
17.2K
Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases
International Journal of Molecular Sciences
|September 28, 2024
Summary
Neurodegenerative diseases involve protein misfolding and aggregation, often linked to aberrant cellular phase separation. This review explores therapeutic strategies targeting protein aggregation to combat these debilitating conditions.
Area of Science:
- Neurobiology
- Biochemistry
- Molecular Medicine
Background:
- Neurodegenerative diseases cause significant human disability and reduced quality of life.
- These diseases share common pathogenic mechanisms, including protein malfunction, structural distortion, and aggregation.
- Cellular phase separation, forming biomolecular condensates, regulates vital neuronal processes.
Purpose of the Study:
- To review the pathological causes of common neurodegenerative diseases (Alzheimer's, Parkinson's, Huntington's).
- To discuss the regulation of key amyloidogenic proteins, focusing on aberrant phase separation and aggregation.
- To introduce therapeutic strategies for neurodegenerative diseases by intervening in protein aggregation.
Main Methods:
- Literature review of neurodegenerative disease pathology.
- Analysis of protein phase separation and aggregation mechanisms.
- Exploration of therapeutic interventions targeting protein aggregation.
Main Results:
- Aberrant phase separation is implicated in protein aggregation within neuronal cells.
- Key amyloidogenic proteins are central to the pathogenesis of neurodegenerative diseases.
- Intervening in protein aggregation presents potential therapeutic avenues.
Conclusions:
- Protein aggregation due to aberrant phase separation is a common hallmark of neurodegenerative diseases.
- Understanding these mechanisms is crucial for developing effective treatments.
- Targeting protein aggregation offers a promising strategy for ameliorating neurodegenerative conditions.
Related Concept Videos
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Parkinson's Disease: Overview
492
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
492
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451

